Evidence map›Paper›PMID 41705241›Full record

ReviewFrontiers in immunology2026

Harnessing pro-inflammatory and immunopathologic immune responses in urinary tract infections for vaccine development: it's all about a balance.

Sivakumar Periasamy, Joyce Lübbers, Susan King, Elise S Hovingh, Leslie van der Fits, Germie P J M van den Dobbelsteen

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sivakumar Periasamy *Infectious Disease and Vaccine, Johnson and Johnson, Spring House, PA, United States.
Joyce Lübbers *Bacterial Vaccine Discovery & Early Development, Johnson and Johnson, Leiden, Netherlands.
Susan KingBacterial Vaccine Discovery & Early Development, Johnson and Johnson, Leiden, Netherlands.
Elise S HovinghBacterial Vaccine Discovery & Early Development, Johnson and Johnson, Leiden, Netherlands.
Leslie van der FitsBacterial Vaccine Discovery & Early Development, Johnson and Johnson, Leiden, Netherlands.
Germie P J M van den DobbelsteenBacterial Vaccine Discovery & Early Development, Johnson and Johnson, Leiden, Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Urinary tract infections (UTIs) cause a high economic burden with frequent medical visits, and in severe cases can lead to hospitalization due to complications like bacteremia or sepsis. UTIs are treated with antibiotics; however, this contributes to the emergence of antimicrobial resistant (AMR) bacterial strains because of misuse and overuse of antibiotics.

Indexed as

Escherichia coli InfectionsEscherichia coli VaccinesUrinary Tract InfectionsUropathogenic Escherichia coliVaccine DevelopmentAdaptive ImmunityAnimalsHumansImmunity, InnateEscherichia coli VaccinesAMRimmunopathologymucosal vaccinesUPECurinary tract infectionuropathogenic E. colivaccines

Identifiers

PMID41705241
PMCPMC12907181

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.